Craft

Outlook Therapeutics

Stock Price

$5.7

2024-10-29

Market Capitalization

$136.5 M

2024-10-29

Revenue

$1.4 M

FY, 2025

Outlook Therapeutics Summary

Company Summary

Overview
Outlook Therapeutics (formerly known as Oncobiologics) is a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics. Its current focus is on monoclonal antibodies in the disease areas of immunology and oncology. 
Type
Public
Status
Active
Founded
2011
HQ
Woodbridge Township, NJ, US | view all locations
Website
https://outlooktherapeutics.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • C. Russell Trenary III

    C. Russell Trenary III, President & Chief Executive Officer

  • Jeff Evanson

    Jeff Evanson, Chief Commercial Officer

  • Lawrence A. Kenyon

    Lawrence A. Kenyon, Chief Financial Officer

LocationsView all

1 location detected

  • Woodbridge Township, NJ HQ

    United States

    485 US-1 Building F, Suite 320, Iselin

Outlook Therapeutics Financials

Summary Financials

Gross profit (Q2, 2026)
($21.9K)
Net income (Q2, 2026)
($4.5M)
Cash (Q2, 2026)
$7.7M
EBIT (Q2, 2026)
($14.0M)
Enterprise value
$149.9M

Footer menu